What the trial was testing
The CHAP enrolled 2,408 patients with hypertension. The study was sponsored by University of Alabama at Birmingham and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was long-term safety (phase 4). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Treating mild high blood pressure during pregnancy reduced serious complications by 18%.
The New England journal of medicine · 2022 · NCT02299414
These findings — that fewer women had preeclampsia, early delivery, or placental problems when treated early — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 2,408 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with hypertension, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
If you have mild high blood pressure and are pregnant, this study shows that taking medication early — rather than waiting until your pressure gets dangerously high — can protect both you and your baby. The treatment reduced the risk of preeclampsia and early delivery without affecting the baby's size. These medications are FDA-approved and widely used in pregnancy. Talk to your OB about whether starting treatment early is right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open hypertension trials
Secondhand Tobacco Smoke and Cardiovascular Disease
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
A Trial of Hydrus Microstent Versus Goniotomy
The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are: * How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare? * How do the safety profiles of these three microinvasive glaucoma surgeries compare? Participants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.